phase II studi idarubicin treatment measur gastric cancer idarubicin new anthracyclin analogu therapeut index doxorubicin daunorubicin varieti murin leukemia solid tumor author multicent phase II trial idarubicin patient advanc gastric cancer seventeen patient measur metastat diseas trial idarubicin dose dose toxic document respons dose-limit toxic myelosuppress data data doxorubicin treatment gastric carcinoma conclus idarubicin minim activ treatment gastric carcinoma 